This is a thoughtful question
Its not a war of oral GLP-1 molecules This September, The New England Journal of Medicine published two major phase 3 trials on oral treatments for obesity: Orforglipron (ATTAIN-1, 3,127 participants, 72 weeks) Mean weight loss: 11.2% at 36 mg 10% weight loss: 54.6% of patients Cardiometabolic improvements (waist, BP, lipids) Safety: frequent GI adverse events, 5 mild pancreatitis cases, modest in heart rate Orforglipron (ATTAIN-1, NEJM): Oral Semaglutide 25 mg (OASIS-4, 307 participants, 64 weeks) Mean weight loss: 13.6% 10% weight loss: 63% of patients Cardiometabolic improvements (HbA1c, triglycerides, inflammation) Safety: GI profile consistent with GLP-1 class, some mild dysesthesia Oral semaglutide 25 mg (OASIS-4, NEJM): What they share Adults with obesity, without diabetes, average BMI ~37, 3545% with prediabetes Clinically relevant weight loss vs placebo Typical GLP-1 GI side-effect profile Key differences Scale & diversity: ATTAIN-1 large, multinational
Get ready with me As a woman, sometimes just putting on jeans can ruin your whole day
Semaglutide 1.0mg (4 Inyecciones) Historial personal o familiar de carcinoma medular de tiroides (MTC) Pancreatitis previa o historial de pancreatitis recurrente Embarazo o lactancia Gastroparesia o trastornos severos gastrointestinales Hipersensibilidad o alergia al medicamento Ozempic Semaglutide GLP-1 Beneficios: La semaglutide es un pptico recetado quese usa para ayudar a las personas a perder peso
PMID: 40934115
Metachronous BrM Refers to metastatic tumours that are diagnosed typically more than 6 months after diagnosis and treatment start of the primary tumour
